Agoracom Blog Home

Posts Tagged ‘THC’

Marijuana Company of America, Inc Announces the Launch of New Website $MCOA.us

Posted by AGORACOM-JC at 8:52 AM on Thursday, May 18th, 2017

15233 mcoa

  • Launched its new corporate website; www.marijuanacompanyofamerica.com.
  • Provides shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans

BONSALL, CA–(May 18, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or “the Company”) (OTC PINK: MCOA), an innovative cannabis and industrial hemp corporation, is pleased to announce the launch of its new corporate website; www.marijuanacompanyofamerica.com.

The new website will provide our shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans, this new site will be the central hub for information about MCOA and the rapidly emerging cannabis and hemp industry.

Since starting the process to become fully reporting and uplisting to a higher financial exchange, the OTCQB, the Company has been engaging with institutional investors and analyzing meaningful M&A opportunities in the cannabis and industrial hemp marketplaces. This new site will be a useful tool in providing investors with updates on these developments.

MCOA recently engaged Hill and DraKoln Media (“H&D”) to develop the new website and provide marketing and brand management support. MCOA looks forward to capitalizing on H&D’s ability to communicate clearly and concisely with investors and consumers alike. They will develop a strong and lasting presence for the Company’s brands. MCOA will take full advantage of H&D’s ability to reach audiences across a variety of demographics related to our industry and expand our reach into new territory.

“We are very happy to finally be launching our new corporate website. David Hill and the Hill & DraKoln group did a wonderful job on the new site and we look forward to them launching the comprehensive branding and marketing strategy they are developing for the Company,” said Mr. Steinberg, MCOA President & CEO.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Contact:
Marijuana Company of America, Inc
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Marijuana Company of America Invests in Global Payout’s MoneyTrac $MCOA.us

Posted by AGORACOM-JC at 9:09 AM on Wednesday, May 3rd, 2017

15233 mcoa

  • Announced an investment of $250,000 in exchange for 15% of MoneyTrac Technology, Inc.
  • Subsidiary of Global Payout (OTC: GOHE)
  • Investment will serve as an excellent resource for MTT in their current objective of establishing the MoneyTrac Technology payment platform

BONSALL, CA–(May 3, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce an investment of $250,000 in exchange for 15% of MoneyTrac Technology, Inc. (“MTT”), a subsidiary of Global Payout (OTC: GOHE).

This investment will serve as an excellent resource for MTT in their current objective of establishing the MoneyTrac Technology payment platform as a major competitor within the alternative banking sector, and more specifically be leveraged in their efforts to extend their marketing campaign to cannabis-related companies who are at the core of MTT’s target market.

In addition to this investment from MCOA, MTT is also pleased to announce that its Board of Directors (“the Board”) has approved the appointment of MCOA CEO, Don Steinberg as a board member with the intention of diversifying their Board through his invaluable experience and knowledge in the early-stage development of companies, and overseeing MCOA shareholder’s investment into MTT.

In addition to his current role at MCOA as founder, CEO and director, Mr. Steinberg was also the founder of Medical Marijuana Inc., the first publicly traded marijuana company in 2009.

“We are pleased and appreciative of the confidence and enthusiasm MCOA has demonstrated with this investment, and we are committed to leveraging it in the most effective manner possible in this all-important stage of our development,” said MTT CEO, James Hancock. “We are also thrilled to welcome Mr. Steinberg to our Board as his experience extends to every corner of business development and operations, from company offerings, product and service management, and to the implementation of strategic marketing campaigns. I have had the distinct pleasure of working with him on several projects over the last decade and look forward to the expertise and energy he will bring to our Board,” Mr. Hancock further remarked.

“I am honored to be given the opportunity to join Mr. Hancock and Ms. Vanessa Luna on the MoneyTrac Board. The electronic payment and compliance features available through the MTT technology platform are the solutions many sectors of our Cannabis industry have been looking for, and I look forward to providing the MTT Board with guidance and support to help move their objectives forward in the most effective way possible,” said Mr. Steinberg.

About Marijuana Company of America (MCOA)
Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.

ABOUT MONEYTRAC, INC.
MoneyTrac Technology, Inc. (www.moneytractechnology.com) is a pioneer in offering a full-service solution for alternative banking and electronic financial solutions and provides all aspects of financial technology including E-Wallet and mobile apps services for businesses and companies in various “high-risk” industries. MoneyTrac’s technology platform allows for its clients to access their financial information from anywhere in the world, in addition to providing tracking and compliance to help them manage and control the flow of all revenue through their business.

ABOUT GLOBAL PAYOUT
Since the Company’s inception in 2009, Global Payout, Inc. (www.globalpayout.com) has been a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. In 2014, Global introduced its first online payment platform called the Consolidated Payment Gateway (CPG), which allowed its enterprise clients to transfer money to international bank accounts, mobile accounts, and prepaid card accounts. The development of the CPG became the foundation for the introduction of its new, state of the art FINTECH payment system in 2017, for both online and mobile applications to allow account holders to maximize an expanded suite of financial services and minimize operational costs. Global will continue to offer their FINTECH payment system to many vertical markets for support of foreign currency exchange and digital currency, including ongoing support of the banking industry and international governments.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact:
Marijuana Company of America, Inc.
IR@mcoa.club

Tetra Bio-Pharma Announces Opening of a New Brunswick Office for Manufacturing & Sales Activities $TBP.ca

Posted by AGORACOM-JC at 4:46 PM on Wednesday, April 12th, 2017

Tbp large

  • Announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities
  • New Brunswick becoming the hub for the Canadian Cannabis industry

OTTAWA, ONTARIO–(April 12, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities. New Brunswick is becoming the hub for the Canadian Cannabis industry.

Tetra is preparing to commercialize several retail products later this year with expected revenues to be generated for the corporation in the fourth quarter. Tetra has already initiated the process to manufacture the first products that act on the cannabinoid system that will be commercialized later this year for sale in Canada and the USA. The Company also intends on commercializing devices (e.g., pipes) for the consumption of medical marijuana in 2017. The Tetra office in Moncton will be responsible to oversee the timely production and launch of the products as well as adhering to the corporation’s budgets.

Tetra has initiated its Phase I clinical trial in March 2017 after manufacturing the PPP001 cannabis drug product at the Ford Pharma contract manufacturing facility in Moncton, New Brunswick. This contract facility developed the proprietary process and equipment required to produce PPP001 pellets and packaging operations. Tetra is also using the contract services of RPC, a New Brunswick provincial crown corporation, to perform its quality control studies to assure that PPP001 conforms to its drug product specifications and quality requirements of a prescription drug.

“We are pleased to announce the opening of a new office in New Brunswick which has become one of the leading provinces in Canada to support the cannabis industry,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will manufacture our PPP001 prescription drug as well as additional scheduled products later this year. We are advancing our projects forward which are on time and on budget, a key priority for the Tetra team. We are now one-step closer towards our goal of commercialization in bringing our innovative cannabis based products to market.”

“We acted quickly to prepare for the development of this industry in New Brunswick,” said Stephen Lund, CEO of Opportunities NB. “The addition of Tetra Bio-Pharma to the province is welcomed news. We have the research, education and production facilities in place for companies to be successful in this rapidly growing industry.”

According to Dr. Guy Chamberland, CSO at Tetra Bio-Pharma Inc., “The use of the facility in Moncton allows Tetra to manufacture the PPP001 drug product for the clinical trial according to the corporation’s timelines and budget. The RPC research and technology organization provides Tetra with the high-level expertise required for assessing the quality aspects of PPP001 while keeping the costs associated with these activities within budget due to RPC not-for-profit status. I can report that the Phase 1 trial is advancing on schedule and according to the corporation’s plans we expect to complete the Phase Ia portion of the study by mid-May. The results of the Phase Ia will provide TBP with a strategic understanding of the commercial potential of marijuana products and allow the corporation to complete its Phase II and III trial plans.”

About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQX:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714

Health Canada urged to clear the way for medical pot insurance $TBP.ca

Posted by AGORACOM-JC at 11:07 AM on Wednesday, April 5th, 2017

Medical marijuana advocates in Alberta say Ottawa needs to expedite safety approvals that would allow insurance companies to provide coverage for costly prescriptions.

  • As the federal government prepares to legalize recreational marijuana by July 2018, Grindle is among the advocates calling on Health Canada  to clear the way for coverage of legally-prescribed pot.

Medical marijuana advocates in Alberta say Ottawa needs to expedite safety approvals that would allow insurance companies to provide coverage for costly prescriptions. (CBC)

Related Stories

Conventional pills did little to ease Jill Grindle’s PTSD and sleep disorder, but within months of turning to medical marijuana the Calgary mother says she was sleeping through the night.

Now she has another worry.

“It’s costing a pretty penny,” she said. “So what I do is I under-medicate greatly. I scrimp and I save and I only use it very sparingly.”

Like most Canadians, Grindle’s standard insurance plan doesn’t cover legally prescribed cannabis. For Grindle that adds up to $1,200 a month if she were to use her full four-gram daily allowance, so she gets by on one gram a day.

As the federal government prepares to legalize recreational marijuana by July 2018, Grindle is among the advocates calling on Health Canada  to clear the way for coverage of legally-prescribed pot.

With the exception of limited coverage for veterans and patients with health care spending accounts, the standard insurance of most Canadians doesn’t reimburse the cost of medical cannabis.

Kait Shane, director of community outreach with Calgary-based Natural Health Services, describes it as the “missing link,” noting Canadians can claim cannabis on their their tax returns and travel with it on federal flights.

“Every patient comes in and is kind of wondering the same thing. Can we be covered; will we be covered?” said Shane, whose Calgary-based company prescribes cannabis at several western locations including Edmonton.

She said the problem is that medical marijuana doesn’t have a drug identification number (DIN); a classification that requires going through a rigorous, expensive approval process required of all new drugs.

Kait Shane with Natural Health Services says out-of-reach cannabis prices push some patients to illegal sources.

“It’s a matter of lobbying … to get Health Canada to recognize it’s not feasible for them to go through the same trials as other drugs,” said Shane, who points out that unlike other narcotics, cannabis has been used for a long time.

Shane worries not insuring medical cannabis will alienate those who can’t afford to get it through licensed producers.

“High costs currently push many patients to seek alternative options through illegal avenues with zero testing protocols,” she said. “The lack of testing could put a patient’s health at risk.”

Joan Weir, director of health police at the Canadian Life and Health Insurance Association, said the process is moving slowly, despite some employers adding coverage.

“There’s not a lot of good research on the impact of adding medical marijuana to your drug program,” said Weir. “So there needs to be a fair bit more research to make employers comfortable on including it as a benefit.”

Health Canada wasn’t immediately available for comment.

Source: http://www.cbc.ca/news/canada/edmonton/health-canada-urged-to-clear-way-for-medical-pot-insurance-1.4053888

MCOA Finalizes Joint Venture Agreement With Bougainville Ventures in Washington State $MCOA.us

Posted by AGORACOM-JC at 1:16 PM on Tuesday, April 4th, 2017

15233 mcoa

  • Finalized the joint venture agreement with Bougainville Ventures, Inc. in Washington State
  • MCOA will invest $1 million in cash in a newly formed entity
  • Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility

BONSALL, CA–(Apr 4, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has finalized the joint venture agreement with Bougainville Ventures, Inc. (“BV”) in Washington State.

MCOA will invest $1 million in cash in a newly formed entity. Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility, which will accommodate a Tier-3 production and processing I-502 tenant that has decades of experience and a proven track record of consistency and quality. MCOA and BV will split equity and profits equally, 50/50.

As turnkey landlords, MCOA and BV will provide our I-502 tenant with a state-of-the-art facility that creates an ideal cultivation environment that they can move into and be fully operational on day one. This enables our tenants to focus on what they do best, producing top quality products and not worrying about maintaining their infrastructure.

Donald Steinberg, MCOA President and CEO, said, “This project will help to expand our operations as an ancillary business into the Washington State market. Achieving this milestone of closing this deal, as well as completing our PCAOB audit at the end of the first quarter are two more pillars of the strong foundation we are building for our shareholders.”

The execution of the agreement is the final step in formalizing the Letter of Intent that was publicly announced on February 15, 2017. This joint venture partnership is formed for the purpose of greenhouse construction, management and commercial leasing to I-502 licensed producers within Washington State only and not beyond its borders.

ABOUT BOUGAINILLE VENTURES, INC.

Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on high-density and high-yielding crops. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to tenant-growers and provides growing infrastructure, as well as landlord services for licensed I-502 producers and processors in the state of Washington.

SAFE HARBOR STATEMENT

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Namaste Enters Into Non-Binding LOI With CannMart, a Late Stage ACMPR Applicant $N.ca

Posted by AGORACOM-JC at 9:51 AM on Tuesday, March 21st, 2017

Nlogo

  • Entered into a non-binding letter of intent with Cannmart Inc.
  • Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations
  • CannMart submitted its application to become a “sales only” licensed producer of medical cannabis

VANCOUVER, BRITISH COLUMBIA–(March 21, 2017) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 

Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ)(OTCQB:NXTTF) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with Cannmart Inc. (“CannMart“) whereby Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“) (the “Contemplated Transaction“). In 2014, CannMart submitted its application to become a “sales only” licensed producer of medical cannabis (the “ACMPR Application“).

The Contemplated Transaction represents a significant strategic maneuver by Namaste in advance of the potential legalization and regulation of cannabis in Canada. The strategic rationale for the Contemplated Transaction includes:

  • Represents a logical expansion of the product portfolio and generates additional recurring revenue streams from existing and new customers throughout Canada. Creates a one-stop shopping platform for Canadian cannabis consumers;
  • Aligns with Namaste’s e-commerce capabilities and dataset of over 50,000 individuals in Canada, which represents a significant competitive advantage in terms of becoming one of the leading online retailers of cannabis;
  • Complements Namaste’s distribution expertise and relationships with the location of CannMart’s proposed facility enabling same day delivery in the Greater Toronto Area and 24-hour delivery within Canada. Namaste will seek to be the leading online retailer of cannabis in terms of fulfillment and customer service; and
  • Enhances the overall financial profile of the Company in terms of additional revenue and margin generation potential. Attractive non-cash purchase price based on comparable public companies within the industry.

CannMart’s ACMPR Application

CannMart’s ACMPR Application and proposed business model are unique in the industry as CannMart has applied only to sell and not produce medical cannabis. Under this model and subject to obtaining a licence from Health Canada, CannMart would have the ability to purchase wholesale medical cannabis from other licensed producers and sell to individual patients in accordance with the ACMPR.

The ACMPR Application has completed the “security clearance” stage and is currently in the “review” stage of the licensing process. CannMart’s proposed facility is a 4,000 sq. ft. industrial building located in Etobicoke, Ontario (the “Facility“). Pursuant to the LOI, the Company will assume all of the going forward liabilities and obligations of CannMart, including the remaining build-out costs needed to prepare the Facility for the final stages of the licensing process and the pre-licensing inspection.

Terms of the Contemplated Transaction

Upon execution of the LOI, Namaste paid $50,000 (the “Initial Payment“) in cash to CannMart’s counsel, to be held in trust and released upon closing of the Contemplated Transaction. If Namaste does not provide CannMart with notice of completion of its due diligence within 30 days of the execution of the LOI, the Initial Payment will become non-refundable. The parties anticipate signing a definitive agreement in mid-late April.

Consideration for the Contemplated Transaction will be satisfied with common shares in the capital of the Company. A portion of common shares of the Company will be issued on closing of the Contemplated Transaction, and the remaining common shares of the Company will be issued upon the occurrence of certain milestones. The share price shall be the five-day trailing volume weighted average price prior to the day on which the Company announces the Contemplated Transaction, subject to compliance with all stock exchange and regulatory requirements.

Clarus Securities Inc. is acting as financial advisor to Namaste in connection with the Contemplated Transaction.

Conditions to Closing

Closing of the Contemplated Transaction is subject to the following:

  • Completion of a definitive share purchase agreement containing representations, warranties and covenants customary in a transaction of this nature;
  • Completion of all financial and legal due diligence;
  • Execution of an employment or consulting agreement with each of CannMart’s existing team members for the purposes of the MMPR Application or longer;
  • Receipt of all director and shareholder approvals, if necessary, and requisite regulatory approvals of each party relating to the Contemplated Transaction;
  • Each of the current directors and officers of CannMart (other than as agreed to by Namaste) having delivered resignations and releases to CannMart; and
  • Such other documentation and closing conditions as are customary for transactions similar to the Contemplated Transaction.

Management Commentary

Mr. Sean Dollinger, President and CEO of Namaste, comments: “The acquisition of CannMart represents a significant strategic transaction for Namaste. One of the core competitive advantages of Namaste is the international customer list we have built, which enables us to enter markets with new product offerings and instantly generate revenues. The addition of consumables to our product offering in Canada is an excellent example of this competitive advantage and we see multiple opportunities to obtain additional licences in international jurisdictions where we have a strong customer foothold.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) - PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Discusses Clinical Program in New Interview with CFN Media

Posted by AGORACOM-JC at 9:19 AM on Tuesday, February 14th, 2017

Tbp large

  • Exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program
  • Interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer

SEATTLE, WA–(Feb 14, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.

Medical marijuana may be legal for roughly 60% of the U.S. population, but the cost of the drug remains prohibitive for many patients in need. Tetra Bio-Pharma aims to undergo FDA-sanctioned clinical trials for dried medical marijuana to secure prescription drug coverage from insurance companies.

Tetra Bio-Pharma held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in late January to advance its PPP001 clinical trial. During the meeting, the FDA provided all the necessary guidance on the design of a Phase I clinical trial on healthy volunteers and its overall development program. The meeting further demonstrates the agency’s willingness to continue the clinical trial to develop a dried marijuana prescription drug.

PPP001 is a dried cannabis product with 9.5% tetrahydrocannabinol (“THC”) and 2% cannabidiol (“CBD”) that is being developed as a prescription drug that will meet the FDA’s high bar for quality and manufacturing. The company’s goal is to be the first to achieve reimbursement from insurance companies for the cost of the prescription, which could prove to be a game-changer for would-be medical marijuana patients that cannot afford the drug.

Tetra Bio-Pharma recently partnered with Sante Cannabis in Montreal to assist in developing its clinical trials. As a leading private medical marijuana clinic, the organization has years of experience in educating patients and ensuring the optimal benefits. The company aims to leverage this expertise to ensure that its clinical trials are properly designed to achieve desired outcomes while helping achieve the organization’s goal of lowering costs for patients.

Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/tetra-bio-pharma-moves-closer-to-clinical-trials/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

 

Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with FDA on PPP001 $TBP.ca

Posted by AGORACOM-JC at 10:21 AM on Monday, January 30th, 2017

Tbp large

  • Completed its pre-IND meeting with the USA Food and Drug Administration  for its PPP001 dried cannabis drug product
  • Meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research
  • FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements

OTTAWA, ONTARIO–(Jan. 30, 2017) - PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).

The FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements. Dr. Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, commented “We could not be more pleased, as the FDA guidance gave us a clear path to progress from early to late phase clinical development. Adhering to the US FDA regulations is part of Tetra Bio-Pharma’s dedication to the commercialization of Cannabis as a prescription controlled drug and the corporations plan to seek reimbursement by insurers for patients.”

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 689-0714

Tetra Bio-Pharma Inc. Announces New Appointment of Dr. Gilles Chamberland, M.D., FRCPC to its Scientific and Clinical Advisory Board $TBP.ca

Posted by AGORACOM-JC at 9:15 AM on Wednesday, January 11th, 2017

Tbp large

  • Announced the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board
  • Board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development

(TORONTO, ONTARIO  Jan. 11, 2017) - PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), is pleased to announce the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development. The nomination of Dr. Chamberland, M.D., to its Advisory Board will provide critical guidance on PPP’s clinical development program with regards to the safety of cannabis drug products and the potential mental health risks associated with the consumption of marijuana.

“Patient safety has been a driving force since the creation of PPP. The use of cannabis has been associated with several important safety issues including potential psychiatric-related events. As a company focused on creating scientific data these risks, as well as others, must be adequately assessed and quantified in a clinical environment. The addition of Dr. Gilles Chamberland, M.D., FRCPC, to our team of accomplished scientific and clinical experts will help us ensure that these potential adverse effects of consuming cannabis will be adequately assessed in our clinical development program and these potential risks will be appropriately communicated to both physicians and patients”, stated Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs.

ABOUT Dr. Gilles Chamberland

Dr. Gilles Chamberland, M.D., FRCPC – Director Professional Services, Medical Psychiatrist, Associate Professor, Department of Psychiatry, Institut Philippe-Pinel de Montréal, Université de Montréal.

Dr. Chamberland received a Bachelor of Law degree from the Université de Sherbrooke, a doctorate in medicine from the Université de Montréal, a diploma in psychiatry from the Université de Montréal, and a diploma of advanced studies in biological and medical ethics of the René Descartes University in Paris. In 2012, he earned the Distinguished Fellow from the Canadian Psychiatric Association and, by 2015 the American Psychiatric Association gave him the same professional recognition. He received a diploma in the subspecialty of Forensic Psychiatry in 2013 from the Royal College of Physicians and Surgeons of Canada. Dr. Chamberland has a vast experience in clinical management of patients suffering from various psychiatric conditions including marijuana induced-psychosis. He is also a well-known author and expert witness in the field on psychiatry.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Tetra Bio-Pharma Inc.
Andre Rancourt, Chief Executive Officer, or
Ryan Brown. VP Business Development and Communications, or
Andre Audet, Executive Chairman
(343) 689-0714
Investors@tetrabiopharma.com